ProBiotix Health plc (‘ProBiotix’), the life sciences business developing probiotics to support cardiometabolic health, is celebrating strong performance through 2024, marked by significant geographic expansion and strengthened scientific partnerships.
The company reported a 13% increase in net sales to £1.88m, alongside a 15% rise in gross profit. This growth was driven by successful market penetration in key regions and increased awareness of the company’s scientifically led probiotic solutions.
A notable highlight was the 56% growth in sales volume through US partner SEED, bolstered by the introduction of ProBiotix products across 2,000 Target stores nationwide. The company’s German partnership with HLH BioPharma also demonstrated remarkable success through 2024, with sales of Lactobact LDL-control increasing by a remarkable 95%.
Adding further success, strategic expansion continued throughout the year with new distribution partnerships established in China, Ukraine, Uzbekistan, Greece, Mexico, and the United States. These agreements position the company for sustained growth in 2025 and beyond.
Steen Andersen, CEO of ProBiotix, commented: “Our performance in 2024 reflects the growing global recognition of our scientific approach to cardiometabolic health with next generation probiotics. The expansion of our distribution network, alongside a new collaborative partnership with Aalborg University, demonstrates the increasing market appetite for evidence-based probiotic solutions – so the sky really is the limit.
“These results are a testament to the exceptional expertise and commitment of our global team and supply chain partners. Our science-led approach to preventative health, particularly in addressing cardiovascular health through precision probiotics, is resonating with health-conscious markets worldwide. This alignment with global wellness trends, combined with our robust scientific validation, positions us perfectly for continued growth.”
As ProBiotix continues to advance microbiome science and expand its global presence, the company plans for further growth throughout 2025. With its continued focus on making the latest probiotic science accessible through consumer-friendly applications, ProBiotix remains committed to leading innovation in the cardiometabolic health and healthy ageing space whilst expanding its footprint in key markets worldwide.
